Literature DB >> 6769612

Abnormal sex steroid secretion and binding in massively obese women.

P G Kopelman, T R Pilkington, N White, S L Jeffcoate.   

Abstract

We have measured the plasma concentrations of sex steroids and sex hormone-binding globulin (SHBG) in twenty-three massively obese women and ten age-matched lean female volunteers. In the obese women increased plasma testosterone (obese 3.2 +/- 0.5 nmol/l controls 1.7 +/- 0.5 nmol/l, P less than 0.3) and androstenedione concentrations (obese 9.7 +/- 1.2 nmol/l, controls 4.4 +/- 0.6 nmol/l, P = less than 0.01) an increased ratio of oestrone:oestradiol (obese 2.4 +/- 0.4, controls 1.0 +/- 0.1, P = less than 0.1) and decreased SHBG levels (obese 30 +/- 4 nmol/l, controls 60 +/- 8 nmol/l, P = less than 0.001) were found. Obesity differed from the polycystic ovary syndrome (in which a similar pattern of changes of sex steroid concentrations and binding are seen) in that it was associated with normal increases in serum luteinizing hormone (LH) follicle stimulating hormone (FSH) levels in response to the administration of LHRH. We conclude that the common occurrence of menstrual abnormalities in obesity results from abnormal secretion and binding of sex steroids. In addition, the unaltered secretion of LH and FSH in the presence of such changes is evidence for a disorder of hypothalamic function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769612     DOI: 10.1111/j.1365-2265.1980.tb02721.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

1.  Molecular Mechanism of TNFα-Induced Down-Regulation of SHBG Expression.

Authors:  Rafael Simó; Anna Barbosa-Desongles; Cristina Sáez-Lopez; Albert Lecube; Cristina Hernandez; David M Selva
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 2.  Estrogens in the breast tissue: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2011-02-01       Impact factor: 2.506

3.  Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease.

Authors:  R Paradisi; S Venturoli; R Pasquali; M Capelli; E Porcu; R Fabbri; C Flamigni
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

4.  Rodent vertical sleeve gastrectomy alters maternal immune health and fetoplacental development.

Authors:  Redin A Spann; William J Lawson; Gene L Bidwell; C Austin Zamarripa; Rodrigo O Maranon; Sibali Bandyopadhyay; Erin R Taylor; Jane F Reckelhoff; Michael R Garrett; Bernadette E Grayson
Journal:  Clin Sci (Lond)       Date:  2018-01-25       Impact factor: 6.124

5.  Sex hormones in obese premenopausal women and their relationships to body fat mass and distribution, B cell function and diet composition.

Authors:  R Pasquali; D Antenucci; N Melchionda; R Fabbri; S Venturoli; D Patrono; M Capelli
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

Review 6.  A systematic review and meta-analysis of physical activity and endometrial cancer risk.

Authors:  Daniela Schmid; Gundula Behrens; Marlen Keimling; Carmen Jochem; Cristian Ricci; Michael Leitzmann
Journal:  Eur J Epidemiol       Date:  2015-03-24       Impact factor: 8.082

7.  Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene.

Authors:  David M Selva; Kevin N Hogeveen; Sheila M Innis; Geoffrey L Hammond
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Serum hormone levels in British and rural Chinese females.

Authors:  D Y Wang; T J Key; M C Pike; J Boreham; J Chen
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

Review 9.  Gender differences in insulin resistance, body composition, and energy balance.

Authors:  Eliza B Geer; Wei Shen
Journal:  Gend Med       Date:  2009

10.  Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C.

Authors:  W Urdl
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.